Overview

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

Status:
Completed
Trial end date:
2020-07-20
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of IONIS-AGT-LRx on plasma angiotensinogen (AGT) and systolic blood pressure (SBP) in uncontrolled hypertensive participants who are on two to three antihypertensive medications.
Phase:
Phase 2
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.